Table 2 Comparison of two US FDA approved CAR-T products for B cell malignancies

YESCARTA Axicabtagene ciloleucel (Yescarta)

CD28 and CD3ζ

2 × 10⁶ CAR-positive viable T cells per kg body weight, with a maximum of 2 × 10⁸ CAR-positive viable T cells.

• Adult patients with relapsed or refractory large B cell lymphoma after two or more lines of systemic therapy, including diffuse large B cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B cell lymphoma, high grade B cell lymphoma, and DLBCL arising from follicular lymphoma.

KYMRIAH™ Tisagenlecleucel (Kymriah)

CD137 (4-1BB) and CD3ζ

Pediatric and young adult B cell ALL (up to 25 years of age):

• For patients 50 kg or less, administer 0.2 to 5.0 × 10⁶ CAR-positive viable T cells per kg body weight intravenously.

• For patients above 50 kg, administer 0.1 to 2.5 × 10⁸ total CAR-positive viable T cells (non-weight based) intravenously.

Adult relapsed or refractory diffuse large B cell lymphoma:

• Administer 0.6 to 6.0 × 10⁸ CAR-positive viable T cells intravenously.

• Patients up to 25 years of age with B cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse.

• Adult patients with relapsed or refractory (r/r) large B cell lymphoma after two or more lines of systemic therapy including diffuse large B cell lymphoma (DLBCL) not otherwise specified, high grade B cell lymphoma and DLBCL arising from follicular lymphoma, excluding primary central nervous system lymphoma.